Tevogen Bio Holdings Inc. (TVGN)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 74/100 (HIGH), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 5.43% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements
- Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
- Tevogen Bio Announces 2026 Annual Meeting of Stockholders
- Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue
- Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization
- Letter to Shareholders from CEO Dr. Ryan Saadi
- Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close
- Tevogen (TVGN) Soars 11% as Firm Gears Up for AI Training Commercialization
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Tevogen Bio Holdings Inc..
Full TVGN Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.